Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Canagliflozin
Drug ID BADD_D00344
Description Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus [L5897], [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes [L5897]. Cardiovascular disease is the most common cause of death in these patients [A177083].
Indications and Usage Canagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Use in type 1 diabetes mellitus patients or in treatment of diabetic ketoacidosis is not recommended.
Marketing Status Prescription
ATC Code A10BK02
DrugBank ID DB08907
KEGG ID D09592
MeSH ID D000068896
PubChem ID 24812758
TTD Drug ID D08DFX
NDC Product Code 50090-5034; 55154-1425; 50090-5029; 70966-0001; 12578-615; 50923-1216; 50458-141; 55111-978; 50458-140; 42385-735; 17314-575; 59651-065; 50090-4364; 46708-886; 14445-017; 17314-577; 12578-611; 55154-1426; 50090-5033
Synonyms Canagliflozin | Invokana | Canagliflozin Hemihydrate | Canagliflozin, Anhydrous | 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene - T777973
Chemical Information
Molecular Formula C24H25FO5S
CAS Registry Number 842133-18-0
SMILES CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Fungal skin infection11.03.05.002; 23.09.02.0010.005361%Not Available
Gait disturbance17.02.05.016; 08.01.02.002--
Gallbladder disorder09.03.02.001--Not Available
Gangrene24.04.05.003; 23.06.06.001; 11.02.01.0030.030254%Not Available
Gas gangrene24.04.05.009; 23.09.01.019; 11.02.02.0080.004213%Not Available
Gastritis07.08.02.001--
Gastrooesophageal reflux disease07.02.02.003--
Gastroenteritis11.01.07.004; 07.19.03.0010.002681%Not Available
Gastroenteritis viral07.19.03.005; 11.05.04.0050.002681%Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal infection11.01.07.012; 07.19.02.0050.000766%Not Available
Gastrointestinal pain07.01.05.005--
Genital candidiasis21.10.03.001; 11.03.03.0020.001149%Not Available
Genital herpes11.05.02.012; 21.10.03.0080.000766%Not Available
Genital rash23.03.13.016; 21.10.01.0090.004978%Not Available
Gingival bleeding24.07.02.010; 07.09.07.001--Not Available
Glomerular filtration rate decreased13.13.01.0090.044806%Not Available
Glycosuria20.02.01.0050.003830%
Glucose urine present13.13.02.0010.006127%Not Available
Glycosylated haemoglobin decreased13.02.02.0120.003830%Not Available
Glycosylated haemoglobin increased13.02.02.0050.034849%Not Available
Gout15.01.06.001; 14.09.01.0010.003830%Not Available
Guillain-Barre syndrome17.09.01.001; 11.07.01.001; 10.04.10.0050.000766%
Haematemesis24.07.02.011; 07.12.02.002--Not Available
Haematochezia24.07.02.012; 07.12.02.003--Not Available
Haematocrit increased13.01.05.0020.001149%Not Available
Haematuria24.07.01.047; 20.02.01.0060.016467%
Blood urine present13.13.02.0020.011106%Not Available
Haemoglobin increased13.01.05.0040.003447%
Haemorrhoids24.10.02.002; 07.15.03.001--
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 18 Pages